Boston Scientific Contour SE Uterine Fibroid Treatment Launch Commences
This article was originally published in The Gray Sheet
Executive SummaryBoston Scientific is supporting the launch of its Contour SE embolic agent for uterine fibroid treatment with trial data showing that embolized patients returned to work three times sooner than those treated with myomectomy
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.